Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 18%
Buy 45%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is well-positioned for growth driven by increasing diagnoses of sleep apnea, an aging population, and rising obesity rates, leading to a structurally expanding market. The company's strategic focus on digital health and investment in clinical data provision enhances its competitive differentiation while allowing for a robust return to shareholders through increased dividends and an aggressive share repurchase strategy. In the latest financial performance, U.S., Canada, and LATAM revenue from masks and other products rose by 12% year-over-year, indicating strong demand and solid revenue growth prospects despite rising operating expenses.

Bears say

ResMed is currently facing a challenging outlook due to the potential market disruption caused by the uptake of GLP-1 drugs, which may negatively impact future sales of its masks and devices used for sleep apnea treatment. Although the company is outpacing market growth, concerns persist regarding its ability to sustain revenue levels in the face of these competing therapies. Moreover, the continued reliance on a significant portion of revenue from the Americas raises risks related to regional market fluctuations and competitive pressures.

ResMed (RMD) has been analyzed by 11 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 45% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 11 analysts, ResMed (RMD) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $294.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $294.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.